Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality

Abstract The efficacy of treating sarcoidosis‐associated pulmonary hypertension (SAPH) with pulmonary vasodilator therapy is unclear. The INCREASE trial showed improvement in 6‐minute walk distance (6MWD) and in decline in functional vital capacity (FVC) in patients with interstitial lung disease an...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shameek Gayen, Sohaib Ansari, Bilal H. Lashari, Huaqing Zhao, Gerard J. Criner, Rohit Gupta, Albert James Mamary
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2023-04-01
Col·lecció:	Pulmonary Circulation
Matèries:	functional vital capacity lung transplant pulmonary hypertension pulmonary vasodilator therapy sarcoidosis
Accés en línia:	https://doi.org/10.1002/pul2.12245
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!